Royal Philips , a global leader in health technology, has launched the Philips ECG AI Marketplace—a centralized platform designed to simplify the adoption and management of AI-powered cardiac diagnostic tools. This innovation empowers cardiac care teams with direct access to multiple vendor algorithms, integrated seamlessly into their existing Philips infrastructure and clinical workflows.
Anumana, a leading AI-driven health technology company focused on transforming cardiac care, is the first partner to feature its technology on the platform. Its FDA-cleared ECG-AI™ LEF (Low Ejection Fraction) algorithm—an advanced tool that detects early signs of heart failure—is now available through the Philips ECG AI Marketplace.
As the use of AI in clinical settings grows, healthcare systems increasingly adopt solutions from various vendors. The Philips ECG AI Marketplace addresses the resulting complexity by consolidating these tools in one ecosystem. It enables U.S. hospitals and health systems to efficiently integrate validated AI algorithms, helping clinicians accelerate ECG interpretation and diagnoses. By reducing the need for custom IT integrations for each tool, the platform also streamlines operations and lowers implementation costs.
“With the Philips ECG AI Marketplace, we’re introducing a more connected and scalable model for AI innovation in cardiac care,” said Stefano Folli, Business Leader, Ambulatory Monitoring and Diagnostics at Philips. “It addresses the growing demand for simplified access to AI-enabled tools, supporting earlier detection of cardiac conditions and improving both clinician and patient experiences. Our collaboration with Anumana exemplifies this vision.”
Anumana’s LEF algorithm is now fully integrated across Philips’ ECG portfolio, including IntelliSpace ECG and Philips cardiographs. The AI tool analyzes standard 12-lead ECGs to detect reduced ejection fraction—a key indicator of potential heart failure—enabling earlier clinical intervention during routine cardiac assessments.
“We’re honored to be the inaugural offering on the Philips ECG AI Marketplace,” said Dr. Simos Kedikoglou, President and COO of Anumana. “This partnership extends the reach of our LEF algorithm through a trusted global platform and lays the foundation for broader access to our expanding suite of point-of-care AI tools. Our technology is backed by clinical research involving over 150,000 patients and nearly 100 peer-reviewed publications. Together with Philips, we’re committed to enabling timely interventions and improving outcomes for patients at risk of heart failure.”
This partnership is part of Philips’ broader strategy to open its ECG ecosystem to third-party AI solutions, enhancing clinical decision-making and simplifying integration for health systems. By bringing powerful AI diagnostics directly to the point of care, Philips is advancing its mission to improve early detection and management of cardiovascular disease on a global scale.